A randomized, double-blinded, placebo-controlled, multi-institutional, cross-over, phase II.5 study of saracatinib (AZD0530), a selective src kinase inhibitor, in patients with recurrent osteosarcoma localized to the lung.
Kristin Baird
No relevant relationships to disclose
Denise K. Reinke
No relevant relationships to disclose
Joseph Gerald Pressey
No relevant relationships to disclose
Leo Mascarenhas
No relevant relationships to disclose
Noah Federman
No relevant relationships to disclose
Neyssa Marina
No relevant relationships to disclose
Sant P. Chawla
Consultant or Advisory Role - CytRx Corporation; Merck; PharmaMar; Roche/Genentech; Sanofi
Research Funding - CytRx Corporation; Merck; PharmaMar; Sanofi
Joanne Pigues Lagmay
No relevant relationships to disclose
John M. Goldberg
No relevant relationships to disclose
Mohammed M. Milhem
Consultant or Advisory Role - Amgen
David Mark Loeb
No relevant relationships to disclose
James E. Butrynski
No relevant relationships to disclose
Katherine A. Janeway
No relevant relationships to disclose
Brian Turpin
No relevant relationships to disclose
Arthur P. Staddon
No relevant relationships to disclose
Sheri L. Spunt
No relevant relationships to disclose
Eve T. Rodler
No relevant relationships to disclose
Scott Schuetze
Research Funding - SARC
Scott H. Okuno
No relevant relationships to disclose
Lee J. Helman
No relevant relationships to disclose